The concept of using a stent to maintain patency of a lumen is not new. As early as 1969, stents were being investigated in the peripheral medal system as a means of preventing restenosis after dilatation by balloon angioplasty (Dotter, 1969 Fabian (Fabian, 1980) was the first to describe the use of a stent or spiral in the lower urinary tract. He placed a metallic endoprosthesis in the prosthetic urethra of poor surgical risk patients in urinary retention as a result of an enlarged prostate. Based upon these results and the successful outcome of others, it became clear that stenting of the lower urinary tract was a workable concept (Fabricius et al., 1983; Flier and Seppelt, 1987) .
The concept of using a stent to maintain patency of a lumen is not new. As early as 1969, stents were being investigated in the peripheral medal system as a means of preventing restenosis after dilatation by balloon angioplasty (Dotter, 1969) . Since then, numerous reports have demonstrated the use of stents in both the peripheral and coronary artery systems (Maass et al., 1982; Dotter et al., 1983; Wright et al., 1985; Palmaz et al., 1987) . Concomitant with the investigation of expandable endovascular metal prosthesis has been the development of prosthetic devices for management of tracheobronchial, gastrointestinal, and genitourinary diseases. We will review the use of endoscopically placed prosthetic devices in the management of diseases affecting these systems.
KEY WORDS: tracheobronchial stents, gastrointestinal stents, genitourinary stents, bronchial stricture, prostatic hypertrophy, biliary tract ENDOSCOPIC PLACEMENT OF PROSTHETIC DEVICES IN GENITOURINARY TRACT Fabian (Fabian, 1980) was the first to describe the use of a stent or spiral in the lower urinary tract. He placed a metallic endoprosthesis in the prosthetic urethra of poor surgical risk patients in urinary retention as a result of an enlarged prostate. Based upon these results and the successful outcome of others, it became clear that stenting of the lower urinary tract was a workable concept (Fabricius et al., 1983; Flier and Seppelt, 1987) .
At the present time, there are a number of intraurethral endoprostheses being developed for use in the lower urinary tract. However, the two permanently implanted intraurethral stents that have been investigated most extensively in both Europe and the United States are the Intraprostatic Stent by advance surgical intervention (San Clemente, California) , and the UroLume Endoprosthesis, However, the UroLume Endoprosthesis has been investigated as a treatment option for three urologic conditions: 1) recurrent bulbar urethral strictures; 2) benign prostatic hypertrophy; and 3) detrusser external sphincter duissynergia. In the discussion that follows, the data relating to the role of the UroLume Endoprosthesis in the lower urinary tract are reviewed.
Recurrent Bulbar Urethral Strictures
The initial experience with this permanently indwelling endoprosthesis in the treatment ofrecurrentbulbar urethral strictures comes from England. In 1988, Milroy and col- leagues (Milroy et al., 1988) reported their preliminary resuits on eight patients. All of these men (mean age: 57 years; range: 33-78 years) hadbeenpreviously treated with a minimum of two direct vision internal urethrotomies (DVIU) and multiple urethral dilatations without success and were awaiting a formal urethroplasty. After first dilating the dense stricture to 30-French (1.0 cm), the UroLume Endoprosthesis was placed across the stenosed area.
In two patients (25%), the endoprosthesis was inserted under radiological control, and in six (75%), the stent was positioned in the bulbar urethra under direct vision using an optical telescope. Endoprosthesis . A total of 17 stents were inserted; 9 patients (75%) received one stent, one man (8%) had two stents, and 2 individuals (17%) had three stents inserted to completely cover the stdctured area. With the followup period ranging from 2 to 13 months (mean: 7 months), no stricture recurred. For the 11 evaluable patients, the mean peak urinary flow rate increased by 200% (7.6 +/-2.3 ml/second pre-insertion to 22.8 +/-8.4 ml/second poststent placement). By 4 to 6 months after placement, the stents were completely covered with urothelium, and thus no longer exposed to the urine during micturation. Untoward effects included transient, mild discomfort at the stent site for 2 to 3 weeks in five men (42%); five other patients complained of mild postvoid dribbling after stent insertion. There was no evidence of encrustations or infection, and no patient complained of alteration in ejaculation or ability to achieve an erection. Ashken and colleagues (Ashken et al., 1991) In a more recent report of 45 surgically unfit patients treated with the UroLume Endoprosthesis, Milroy and colleagues, indicated that 42 (93%) were pleased with the outcome; all were "passing urine normally with sufficiently reduced residual urine volumes" (Milroy, 1991) . Most patients, however, suffered urgency, frequency, and occasional urge incontinence following stent placement; these symptoms tended to resolve within several months, as the endoprosthesis became covered with epithelium. Most often, the stem becomes covered with urothelium within 4 to 6 months' time, which is somewhat faster than that which occurs in the bulbar urethra. At 6 to 9 months after stent placement, these investigators did notice a significant amount of hyperplastic tissue growing through the intertices of the wall of the stent. However, by 12 to 18 months post-stent insertion, this had subsided markedly and was of no concern. No encmstations were observed on any part of the endoprosthesis located within the prostatic urethra. However, if the proximal end of the stent is allowed to extend across the bladder neck into the bladder, "fine encmstations" can develop on this aspect ofthe device 6 to 12 months after placement. In the Milroy series, it has been necessary to remove five stents. All devices were removed without difficulty. Two were not positioned properly at the time of deployment and were removed immediately, and a second stent was inserted; two others were removed 4 weeks after placement, and one was taken out 11 months after insertion. The technique for removing an endoprosthesis after it has become covered with epithelium is as follows. Once the overlying epithelium has been resected with a low-current resectoscope, the stent is jarred from it's bed in the prostatic urethra with a forceps. The stent is then grasped approximately 0.5 cm from its distal edge and pulled gently; it will lengthen and decrease in diameter (much like a Chinese finger toy) so that it can be pulled inside a resectoscope sheet and removed without trauma to the urethra or the external urinary spinchter have readily undergone a transurethral resection of the prostate gland. All patients were evaluated prior to stent placement and in followup with a standard symptom questionnaire, peak urinary flow rate, postvoid residual urine volume, and cystoscopic examination. The patients found to have a large, median lobe or considered to have a hypotonic bladder were excluded from participation. The resuits at 12 months followup were excellent. The total symptom scored decreased from 15.0 +/-5.5 pre-insertion to 6.3 +/-5.8 (p < 0.001). With voided volumes in excess of 150 cc, the peak urinary flow rate increased from 8.6 +/-3.5 cc/second pre-insertion to 15.6 +/-6.2 cc/second (p < 0.001). The postvoid residual urine volume decreased from a 129 +/-14.6 cc to 24 +/-44 cc (p < 0.001). By 6 months, 55% of the endoprostheses were completely covered with epithelium; 45% still had some aspect of the stent exposed at the bladder neck. There was no significant difficulty with infection, erosion, migration, continence, or potency; 67% ofthe patients, however, had some irritative symptoms (urgency, frequency, or dysuria) for at least 1 month after stent placement. Nine Supraspinal cord injuries most often result in some degree of detrusor external sphincter dyssynergia (Barkin et al., 1983) . The majority of patients develop significant detrusor-external sphincter dyssynergia and require theraputic intervention. The two standard treatments are: 1) anticholinergic therapy (to decrease uninhibited bladder contractions and improve vesical compliance) with clean intermittent catheterization, and 2) external striated sphincterotomy to reduce bladder outlet resistance. The former option is only a consideration ifthe patient has sufficient manual dexterity. The latter treatment, on the other hand, does not always result in a favorable outcome. The results of endoscopic external sphincterotomy have been variable; overall, the success rate of this procedure is approximately 79 to 90%, as destruction of the entire external urinary sphincter is not always technically easy (Whitmore et al., 1978 (Cwikiel et al., 1993) . There were no immediate complications, although ingrowth of the tumor was seen in eight patients. Two of the patients had occlusion of the stent by tumor and required laser resection to re-establish luminal patency.
The Gianturco metallic stent was used by Iwasaki and collegues (Iwasaki et al., 1993) to bridge a malignant stricture of a esophagojejunostomy. Truong and collegues (Truong et al., 1992 ) also reported palliative treatment of malignant gastric outlet obstruction using a self-expanding metal stent.
Biliary Duct and Pancreatic Duct Stenting
The placement of biliary and pancreatic endoprostheses is also receiving intensive study and experimentation. Endoscopic stent placement has become accepted palliation for patients with inoperable malignant biliary tract obstruction. Specific conditions that may be amenable to stenting include pancreatic and biliary carcinoma, or metastatic lesions that either compress or infiltrate the biliary tree such as carcinoma of the gallbladder, carcinoma of the stomach, or cancers arising in the colon, breast, etc. The major condition that has benefitted from endoscopic stenting has been pancreatic adenocarcinoma. Ofthis group ofpatients, 22 percent also had malignant hilar obstruction.
The success rate for endoscopic placement of biliary stents is approximately 80 to 93% and the overall success of insertion is judged by evaluating complications encountered in obtaining the goals of the procedure. A preliminary goal in the treatment of malignant obstruction is the relief ofjaundice. Kodakin and Starnes (Kodakin and Starnes, 1992 ) have compared the 10 French and the 11.5 French polyethylene biliary stents, and their effectiveness in obtaining relief of icterus, and decline of total bilirubin. They concluded that there is no significant advantage between these stent sizes. However, the stent patency is approximately twice as long for the 10 French polyethylene stent compared to the 7 French stent. There is a slight tendency for a higher complication rate using the larger stent (Pedersen, 1993) .
The occlusion rate most certainly impacts on the acceptance of stenting of the biliary ductal system as palliative therapy. The occlusion rate for a 10 French or 11.5 French stent at 3 months is 42%, and at 6 months is 10.8% (Davids et al., 1992) . Furthermore, a worse clinical response and poorer survival is seen in the group of patients who have undergone stenting for metastatic cancer (Frakes et al., 1993) .
The search for a better stent is primarily based on the ease of insertion and stent patency. This search has led to the use of metal expandable stents. The University of Amsterdam investigators have compared an expandable metal stent with a polyethylene stent (Davids et al., 1992) . The median patency for the first stent insertion was significantly prolonged in patients with a metal stent compared with the polyethylene stem, 273 days versus 126 days, respectively. The major cause of stent dysfunction was tumor ingrowth in the metal stent group, and sludge deposit in the polyethylene group. When stent blockage was encountered, a polyethylene stent was inserted. Of those patients in the metal stent group, 14 required a polyethylene stent insertion, and no further occlusions were encountered. In the group who had a polyethylene stent initially inserted, 23 required an additional stent inserted.
Eleven of the 23 (48%) who had a new polyethylene stent inserted had an additional episode of occlusion. This fact suggests that re-occlusion is more likely to occur when the endoscopist uses only polyethylene stents.
Since plastic stents are removable, they have been employed in the treatment of benign biliary strictures. A nonrandomized study by Davids (Davids et al., 1993 retrospectively compared surgical management and endoscopic management of benign biliary strictures. Endoscopically placed biliary stents, which were exchanged every third month for a 1 year period, were compared to patients who were surgically managed. Seventeen percenthadrecurrent stricture afterundergoing endoscopic dilatation and stenting. Another way that this result can be stated is that 83% oftheir strictures were patent after being submitted to endoscopic care, while the literature frequentl states that surgical management of strictures has an 80% long-term success. The authors conclude that this practice scheme is an acceptable way to initially manage strictures, and that the surgical repair should be reserved for patients who have complete transection of the duct, failed previous surgical repair, or failed an endoscopic treatment program. This recommended approach seems to be an oversimplification of a very complex situation.
Millis (Millis et al., 1992) (Sherman et al., 1993) . Similar changes have been observed in humans (Kozarek, 1990 Dumon, 1990; lnsall and Morritt, 1991; Montgomery, 1965; Montgomery, 1968 Neville etal., 1972 Oflowski, 1987; Paliero and Shepherd, 1974; Simonds et al., 1985; Uchida et al., 1988; Wallace et al., 1986 Westaby et al., 1982 Westaby and Shepard, 1983) . Three basic types ofprosthetic devices are currently available: 1) molded silicone prostheses, 2) expandable metal prostheses, or 3) combinations ofmetal and silicone.
Dumon (Dumon, 1990) (Rousseau etal., 1992 One patient has had the prosthetic device in place for more than 48 months. The major complication has been obstruction by inspisated secretions. One patient experienced stent dislodgement and one patient had a stent removed due to intractable cough. Our experience supports the use of silicone prostheses in selected patients with airway obstruction due to malignant or benign processes.
The ideal prosthetic device for tracheobronchial obstruction has not yet been witnessed. Depending on the circumstances, the silicone prosthesis ofthe Dumon type may have advantages over the self-expanding metal stents. Clearly, for the benign stricture in patients who are not surgical candidates, the silicone prosthesis is the instrument of choice. As more development occurs, the metal self-expanding stents may find more appropriate applications. The combined metal silicone stents that are currently under development may also provide a new class of stents that will be more appropriate for patients with airway obstruction.
Summary
Endoscopic placement of endoluminal prosthetic devices continues to expand. Significant palliation can be accomplished in patients with diseases that effect not only the vascular system, but also the genitourinary, gastrointestinal, and tracheobronchial tree. Symptoms ofrecurrent bulbar urethral strictures, benign prostatic hypertrophy, and detrusor external sphincter dyssynergia may be managed in some patients using these new devices. Obstruction of the esophagus by carcinoma or obstruction of the biliary or pancreatic ducts may also be palliated using new prosthetic devices. Malignancies and benign processes causing airway obstruction with resulting dyspnea may be managed by dilatation and placement ofprosthetic devices in the tracheobronchial tree. Although devices are available for each ofthe above conditions, further development and investigation needs to be undertaken to improve both methods of application as well as analyze long-term results in these disorders.
